Nasdaq · CIK 0000890821
ENVB Enveric Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Jun 3, 2026.
Enveric Biosciences, Inc. (ENVB) has 26 SEC Form 4 filings on file from 8 insiders, the latest filed on Jun 3, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Enveric Biosciences, Inc., scored.
Transactions
Every row filed, 26 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Sheila DeWitt director | AGrant or award Common Stock | +18,518 | $0.00 | $0 | 26,306 | Jun 3, 2026 |
| Jun 1, 2026 | Michael D Webb director | AGrant or award Common Stock | +18,518 | $0.00 | $0 | 26,416 | Jun 3, 2026 |
| Jun 1, 2026 | Frank Pasqualone director | AGrant or award Common Stock | +18,518 | $0.00 | $0 | 26,423 | Jun 3, 2026 |
| Jun 1, 2026 | Marcus Schabacker director | AGrant or award Common Stock | +18,518 | $0.00 | $0 | 26,418 | Jun 3, 2026 |
| Jun 1, 2026 | George A. Kegler director | AGrant or award Common Stock | +18,518 | $0.00 | $0 | 26,418 | Jun 3, 2026 |
| Jun 1, 2026 | Joseph Edward Tucker Chief Executive Officer | AGrant or award Common Stock | +201,124 | $0.00 | $0 | 271,479 | Jun 3, 2026 |
| Jun 1, 2026 | Peter J. Facchini Chief Innovation Officer | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 27,755 | Jun 3, 2026 |
| Jun 1, 2026 | Kevin Michael Coveney Chief Financial Officer | AGrant or award Common Stock | +133,333 | $0.00 | $0 | 180,746 | Jun 3, 2026 |
| Dec 23, 2025 | Frank Pasqualone director | AGrant or award Common Stock | +7,633 | $0.00 | $0 | 7,904 | Dec 30, 2025 |
| Dec 23, 2025 | George A. Kegler director | AGrant or award Common Stock | +7,633 | $0.00 | $0 | 7,900 | Dec 30, 2025 |
| Dec 23, 2025 | Marcus Schabacker director | AGrant or award Common Stock | +7,633 | $0.00 | $0 | 7,900 | Dec 30, 2025 |
| Dec 23, 2025 | Joseph Edward Tucker Chief Executive Officer | AGrant or award Common Stock | +60,296 | $0.00 | $0 | 70,355 | Dec 30, 2025 |
| Dec 23, 2025 | Michael D Webb director | AGrant or award Common Stock | +7,633 | $0.00 | $0 | 7,898 | Dec 30, 2025 |
| Dec 23, 2025 | Sheila DeWitt director | AGrant or award Common Stock | +7,633 | $0.00 | $0 | 7,788 | Dec 30, 2025 |
| Dec 23, 2025 | Kevin Michael Coveney Chief Financial Officer | AGrant or award Common Stock | +40,198 | $0.00 | $0 | 47,413 | Dec 30, 2025 |
| May 8, 2025 | Kevin Michael Coveney CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +74,150 | $0.00 | $0 | 86,584 | May 12, 2025 |
| May 8, 2025 | Joseph Edward Tucker CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +98,866 | $0.00 | $0 | 120,711 | May 12, 2025 |
| May 8, 2025 | Peter J. Facchini CHIEF INNOVATION OFFICER | AGrant or award Common Stock | +24,717 | $0.00 | $0 | 33,058 | May 12, 2025 |
| Oct 9, 2024 | Kevin Michael Coveney CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 186,500 | Oct 11, 2024 |
| Oct 9, 2024 | Sheila DeWitt director | AGrant or award Common Stock | +27,845 | $0.00 | $0 | 27,845 | Oct 11, 2024 |
| Oct 9, 2024 | Peter J. Facchini CHIEF INNOVATION OFFICER | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 130,856 | Oct 11, 2024 |
| Oct 9, 2024 | Joseph Edward Tucker CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +161,633 | $0.00 | $0 | 335,829 | Oct 11, 2024 |
| Oct 9, 2024 | Frank Pasqualone director | AGrant or award Common Stock | +47,733 | $0.00 | $0 | 48,733 | Oct 11, 2024 |
| Oct 9, 2024 | Michael D Webb director | AGrant or award Common Stock | +47,733 | $0.00 | $0 | 47,733 | Oct 11, 2024 |
| Oct 9, 2024 | Marcus Schabacker director | AGrant or award Common Stock | +47,733 | $0.00 | $0 | 48,053 | Oct 11, 2024 |
| Oct 9, 2024 | George A. Kegler director | AGrant or award Common Stock | +47,733 | $0.00 | $0 | 48,053 | Oct 11, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Kevin Michael CoveneyChief Financial Officer
- Sheila DeWittdirector
- Peter J. FacchiniChief Innovation Officer
- George A. Keglerdirector
- Frank Pasqualonedirector
- Marcus Schabackerdirector
- Joseph Edward TuckerChief Executive Officer
- Michael D Webbdirector
Questions about ENVB
Answered from the filings on this page, as of the latest one.
Are insiders buying ENVB?
No. In the last 90 days no insider at Enveric Biosciences, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ENVB on the open market?
No open-market trade has been scored at Enveric Biosciences, Inc.. The latest Form 4 on file was filed on Jun 3, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Enveric Biosciences, Inc.?
8 people have filed a Form 4 at Enveric Biosciences, Inc., among them Kevin Michael Coveney (Chief Financial Officer), Sheila DeWitt (director), Peter J. Facchini (Chief Innovation Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.